Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Higher arterial age linked to risk of cancer, kidney disease
High coronary artery calcium score a measure of arterial ageing puts people at greater risk not only for heart and vascular disease but also for non-cardiovascular diseases such as cancer, chronic kidney disease and lung diseases, says a study.
- Read more about Generic drug can reduce treatment cost for cancer patients
Patients suffering from chronic myeloid leukemia (CML) a rare form of cancer can get huge financial benefits if they start using the generic form of drug Gleevec, the patent of which expired in January this year, a study said.
- Read more about Novel method to harvest stem cells developed
Scientists have developed a new method for harvesting stem cells, which is less invasive and reduces side effects for donors.The new method eliminates the need for the patient to take growth factor injections to increase cell numbers before a transplant.
- Read more about Baxter start US clinical trial for VIVIA investigational HD system
Baxter International Inc. announced enrollment of the first patient in a US clinical trial for VIVIA, an investigational home haemodialysis (HD) system being developed by Baxter and DEKA Research & Development Corporation.
- Read more about Novimmune’s NI-0501 granted breakthrough therapy designation by US FDA
Novimmune, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NI-0501 for the treatment of patients with primary HLH with refractory disease, or with recurrent or progressive disease during conventional therapy. NI-0501 is a fully human, anti-interferon-gamma (IFNγ) monoclonal antibody discovered and developed by Novimmune.
- Read more about Takeda, Frazier healthcare launch outpost medicine to develop new therapeutics in Urology & Gynaecology
Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners announced the formation of Outpost Medicine, a biopharmaceutical company focused on the development of new treatments of urologic and gynaecologic diseases and disorders.
- Read more about Aralez resubmits to FDA new drug application for YOSPRALA
Aralez Pharmaceuticals Inc. announced that it has resubmitted to the U.S. Food and Drug Administration ("FDA") the New Drug Application ("NDA") for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.
- Read more about ResApp completes successful Pre-Submission meeting with the US FDA
ResApp Health Limited , announced a positive outcome from its recent Pre-Submission Meeting with the United States Food and Drug Administration (FDA) regarding ResApp’s diagnostic mobile software application, ResAppDx.
- Read more about Aeglea BioTherapeutics announces FDA acceptance of Its IND application for AEB1102
Aeglea BioTherapeutics, Inc., announced the U.S. Food and Drug Administration (FDA) has accepted the company’s investigational new drug (IND) application for AEB1102 for the treatment of Arginase I deficiency, a urea cycle disorder that results in elevated levels of the amino acid arginine, which can lead to a range of complications including intellectual disability and spasticity.
- Read more about Celator announces phase 3 trial for VYXEOS™ (CPX-351)
Celator Pharmaceuticals, Inc. announced positive results from the Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3. The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival. Data will be submitted for presentation at the American Society of Clinical Oncology 2016 Annual Meeting.

[adsense:336x280:8701650588]